Participated · Series F · Aug 2021

Yuanxin Technology builds a digital healthcare platform that connects doctors, hospitals, pharmaceutical companies, insurers and patients via services including Miaoshou Doctor, Yuanxin Pharmacy and Yuanxin Huibao. It provides in-hospital and out-of-hospital integrated diagnosis and treatment solutions, one-stop pharmacy and hospitalization payment, digital-driven marketing and patient rehabilitation support for pharmaceutical companies, and full-stack insurance operation solutions. After this financing, the company plans to expand its service network for discharged patients, customize post-visit disease course management for multi-disease patients, and accelerate construction of a digitized hospital network and a full-cycle patient portal. Yuanxin also intends to further develop multi-disease and multi-form health insurance products and build digital infrastructure—IT and data systems—that connect patients, doctors, hospitals, pharmaceutical companies, and insurers. Founded in 2015, the company says it has taken a leading role in the “hospital-medication-insurance-patient” model and has maintained sustained rapid growth and top industry positioning. The company completed over ¥1.5 billion in Series F financing, which will support its expansion and digitalization plans. Beijing Yuanxin Technology Co., Ltd is a specialist in digital healthcare and chain pharmacies, operating both digital health services and pharmacy chains. The company focuses on integrating digital healthcare solutions with traditional pharmacy operations. It is identified by its Beijing affiliation in the company name. Recently it completed a major financing round, indicating investor confidence in its business model. No operating metrics or revenue figures were disclosed in the article. Future plans were not specified in the article. Beijing Yuanxin Technology Company Limited, also known as Miaoshou Doctor, is described in reporting as a digital/internet health service provider. The company operates in online health services under the Miaoshou Doctor name. According to the coverage, it has secured an aggregate of 600 million yuan, roughly $85 million. That amount was raised in a Series D1 round. Investors named in the reporting include Sequoia and Qiming, alongside other unspecified participants. The article does not disclose additional operating metrics, valuation, or founding-year information. Miaoshou Doctor is a China-based company reported in DealStreetAsia's roundup of Chinese funding news. The article states the company completed a 500 million-yuan Series C+ financing (about $72.77 million). The report identifies Starquest Capital as the lead investor for the round. The article does not provide details on Miaoshou Doctor’s core product, operating metrics, or future plans. This funding announcement was reported alongside other China tech deals, including SenseTime’s investment in WeRide.

Participated · Series F · Aug 2021

Yuanxin Technology operates a multi‑business healthcare matrix (including Miaoshou Doctor, Yuanxin Pharmacy, Yuanxin HuiBao and Yuanxin Medical Technology) that links patients, doctors, hospitals, pharma and insurers through digital and offline services. The company focuses on building an out‑of‑hospital disease‑management network and an in‑hospital digital smart service network to provide integrated, full‑cycle care and payment solutions. It offers digital marketing, sales, R&D and patient‑management solutions for pharma, one‑stop services for doctors (education, multi‑site practice, patient management) and full‑stack operational solutions for insurers. Future plans described in the articles include expanding patient out‑of‑hospital service networks, accelerating construction of a digital hospital network, developing multi‑disease commercial health insurance products, and building an IT and data infrastructure that connects stakeholders. Founded in 2015 and headquartered in Beijing, the company positions itself as a market leader capturing synergies across medical, pharma and insurance ecosystems. The articles highlight a diversified top‑tier investor base and continued strategic capital support as validation of its growth potential.